Menopause-Related Weight Gain: Racial and Ethnic Disparities

Why Race and Ethnicity Shape Menopausal Weight Gain

Race and ethnicity influence the timing, distribution, and metabolic consequences of weight gained during the menopause transition, independent of socioeconomic factors. The Study of Women's Health Across the Nation (SWAN), which tracked 3,302 women from five racial/ethnic groups for more than 20 years, remains the largest and most cited longitudinal dataset on this question. SWAN's published findings show that weight-gain trajectories diverge well before the final menstrual period and that those divergences widen through early postmenopause.

What SWAN Revealed About Baseline Differences

At enrollment, Black participants in SWAN already had higher mean BMI values than white, Chinese, or Japanese participants. Sternfeld et al. confirmed that physical activity moderated weight gain differently across groups, with Black women gaining weight even when meeting activity guidelines that protected white women. The implication: a single lifestyle prescription does not carry equal protective effect across populations.

The Role of Estrogen Receptor Variation

Polymorphisms in the estrogen receptor alpha gene (ESR1) vary by ancestry and predict the degree of fat redistribution from peripheral to central depots during menopause. A 2021 analysis in the Journal of Clinical Endocrinology and Metabolism found ESR1 variants more prevalent in women of African ancestry and associated with greater visceral adiposity at equivalent estrogen decline. This partially explains why BMI fails as a proxy for metabolic risk when applied uniformly across ancestries.

Black Women: Higher Baseline Weight, Faster Gain, Greater Cardiovascular Burden

Black women enter perimenopause at higher average BMIs and accumulate abdominal fat more rapidly than white women with identical estrogen trajectories. The SWAN Heart substudy documented that aortic calcification progressed faster in Black participants during the late perimenopause window, linking visceral fat accumulation directly to vascular risk.

Weight Gain Rates in SWAN

Across 20 years of SWAN follow-up, Black women gained approximately 0.55 kg per year during perimenopause compared to roughly 0.44 kg per year in white women. Matthews et al. reported these figures and noted that the gap persisted after controlling for caloric intake and baseline BMI. That 0.11 kg/yr difference compounds to roughly 2.2 additional kilograms over 20 years from the menopausal transition alone.

Cardiovascular Mortality Disparity

Black postmenopausal women face approximately 40% higher cardiovascular disease (CVD) mortality than non-Hispanic white women of the same age. The American Heart Association's 2024 Heart Disease and Stroke Statistics attribute part of this excess to visceral adiposity accumulation during and after menopause, compounded by higher rates of hypertension and diabetes in this demographic.

Hormone Therapy Uptake Gap

National survey data show non-Hispanic white women use menopausal hormone therapy (MHT) at roughly twice the rate of Black women. A JAMA Internal Medicine analysis found that lower MHT uptake among Black women reflects clinician under-prescribing, historical medical mistrust rooted in documented research exploitation, and cost barriers. This gap matters metabolically because estrogen-based MHT attenuates the shift from peripheral to visceral fat deposition that drives cardiovascular risk during the menopause transition.

Hispanic and Latina Women: Central Adiposity at Lower Absolute Weight

Hispanic and Latina women show disproportionate intra-abdominal fat accumulation during menopause, often at BMI values that clinical algorithms classify as "normal weight." The Hispanic Community Health Study/Study of Latinos (HCHS/SOL), which enrolled 16,415 adults across four U.S. Sites, documented that Latina women had higher rates of metabolic syndrome than non-Hispanic white women even when BMI was similar.

Visceral Fat Without Elevated BMI

A 2019 study in Menopause journal measured dual-energy X-ray absorptiometry (DEXA) body composition in perimenopausal Latina women and found visceral adipose tissue (VAT) volumes 18% to 22% higher than in non-Hispanic white women at the same BMI. Clinicians relying on BMI alone therefore underestimate cardiometabolic risk in this population at the time of the menopause transition.

Diabetes Risk During Perimenopause

Type 2 diabetes incidence spikes during perimenopause in Hispanic women. Appiah et al. In Diabetes Care showed that among SWAN participants, Hispanic women had a 2.5-fold higher incidence of diabetes during the menopausal transition compared to non-Hispanic white women, a risk that weight gain during this period directly amplifies.

Language and Access Barriers to Treatment

Hispanic women face disproportionate barriers to weight-management pharmacotherapy. A 2023 Health Affairs analysis found Spanish-speaking patients were 34% less likely to be prescribed GLP-1 receptor agonists for obesity than English-speaking patients with identical BMI and comorbidities, a disparity that intersects with menopausal weight-management needs.

Asian Women: Metabolic Risk at "Normal" BMI

Asian women, including those of East Asian and South Asian ancestry, accumulate visceral fat at lower absolute body weights than Western reference populations. The standard WHO BMI cutoff of 25 for overweight was developed in predominantly European cohorts. The WHO Expert Consultation on BMI in Asian Populations recommended that Asian-specific risk thresholds begin at BMI 23 for overweight and 27.5 for obesity.

Why Standard Cutoffs Fail Asian Patients

At BMI 24, a Japanese-American woman and a white woman look identical on a standard risk calculator. DEXA imaging data from the Multi-Ethnic Study of Atherosclerosis (MESA) show that Chinese-American women carry 30% to 40% more visceral adipose tissue per unit of BMI than non-Hispanic white women. Menopause accelerates this disparity because estrogen loss preferentially shifts fat to visceral depots, and Asian women start that transition with less subcutaneous buffer.

Breast Cancer and HRT Considerations

Asian women have lower baseline breast cancer risk than white women, but estrogen-receptor-positive breast cancer incidence is rising among U.S.-born Asian women. A 2022 JAMA Oncology report noted that hormone therapy decision-making must account for acculturation-related risk changes. Clinicians should not assume that lower baseline risk means hormone therapy is automatically safe in all Asian patients; individualized shared decision-making using the NAMS 2022 Hormone Therapy Position Statement framework is appropriate.

Weight Management Pharmacotherapy Dosing

Asian women were systematically under-enrolled in GLP-1 trials. The SCALE Obesity trial (liraglutide 3.0 mg, N=3,731) enrolled fewer than 5% Asian participants. A dedicated Asian subgroup analysis of semaglutide 2.4 mg from STEP-6, conducted in Japanese and Korean adults, showed 13.2% mean weight loss at 68 weeks. Dose titration in Asian women may need to start lower given reported greater sensitivity to GI adverse effects in this population.

White Women: Reference Group Caveats and Intra-Group Variation

Non-Hispanic white women form the reference group in most menopause trials, which means published efficacy data apply most directly to them. The Women's Health Initiative (WHI), which enrolled 161,808 postmenopausal women, was 84% non-Hispanic white. Generalizing its hormone therapy risk-benefit findings to other racial groups introduces error.

Socioeconomic Confounding Within the White Category

"Non-Hispanic white" is not metabolically homogeneous. Appalachian white women show obesity prevalence and metabolic-syndrome rates closer to national figures for Black and Hispanic women, driven by poverty, food insecurity, and limited healthcare access. Treating all white women as a low-risk reference group misses this heterogeneity.

MHT Uptake and Prescribing Patterns

White women do receive MHT at higher rates, and data from the 2021 Menopause Society Clinical Practice Survey show clinician prescribing confidence is highest for this group. The same survey found that only 31% of clinicians felt "very comfortable" discussing MHT with Black patients versus 58% for white patients, a disparity that shapes who gets metabolic benefit from hormone therapy.

Indigenous and American Indian/Alaska Native Women: The Data Gap

Data on menopause-related weight gain in American Indian and Alaska Native (AIAN) women are scarce to the point of being a research failure. AIAN women have the highest age-adjusted obesity prevalence of any U.S. Demographic group at approximately 49.9%, per CDC 2023 surveillance data. SWAN enrolled no AIAN participants. The Strong Heart Study tracked cardiovascular disease in AIAN adults but did not systematically measure menopausal transition weight dynamics.

What Limited Evidence Shows

A cross-sectional analysis in the American Journal of Epidemiology using Indian Health Service records found that AIAN women experienced earlier menopause onset (median age 48.5 vs. 51.4 in white women) and had higher postmenopausal BMI at every age bracket measured. Earlier menopause means a longer postmenopausal estrogen-deficient window, compounding cumulative visceral fat accumulation and cardiovascular risk.

Clinical Implication

Any clinician treating AIAN women should screen for metabolic syndrome starting at perimenopause, not at the standard postmenopausal threshold, and should apply Asian-style lower BMI risk cutoffs as a precaution given the under-researched metabolic phenotype in this population.

GLP-1 Receptor Agonists and Weight Loss: What Trial Diversity Data Tell Us

GLP-1 receptor agonists are now first-line pharmacotherapy for obesity-related weight management in postmenopausal women who meet criteria. Their efficacy data come predominantly from trials with limited racial diversity.

STEP-1 and Demographic Breakdown

In STEP-1 (semaglutide 2.4 mg, N=1,961), participants achieved 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. Published in NEJM. The trial was 75% white, 8% Black, and 12% Hispanic. Subgroup analyses by race were not powered for statistical significance. The FDA label for Wegovy carries no race-specific dosing guidance.

SCALE Obesity Subgroup Signal

In SCALE Obesity (liraglutide 3.0 mg, N=3,731), a post-hoc subgroup analysis showed numerically smaller absolute weight loss in Black participants (approximately 4.2% vs 8.0% overall) though the subgroup was too small for definitive conclusions. This signal warrants prospective investigation.

Tirzepatide Data

The SURMOUNT-1 trial (tirzepatide, N=2,539) achieved up to 22.5% mean weight loss at 72 weeks with the 15 mg dose. Published in NEJM. SURMOUNT-1 enrolled approximately 14% Black and 24% Hispanic participants, making it modestly more diverse than STEP-1. Race-stratified efficacy data have not been published as a primary analysis.

Menopause-Specific GLP-1 Prescribing Gaps

No completed randomized trial has specifically enrolled postmenopausal women of color to test GLP-1 efficacy in the context of menopause-driven weight gain. The Endocrine Society's 2023 Obesity Pharmacotherapy Clinical Practice Guideline recommends GLP-1 agents for adults with BMI ≥30 (or ≥27 with comorbidities) without race-specific modification. That gap in guidance leaves clinicians extrapolating from majority-white trial data.

Menopausal Hormone Therapy: Race-Specific Risk-Benefit Considerations

MHT reduces the menopausal shift from subcutaneous to visceral fat. Its cardiovascular risk profile differs by timing relative to menopause onset (the "timing hypothesis"), and this timing effect may interact with race-specific baseline cardiovascular risk.

The Timing Hypothesis and Racial Risk Differences

The WHI Memory Study and subsequent re-analyses established that women who started MHT within 10 years of menopause had reduced coronary artery disease risk, while those starting 20 or more years post-menopause did not. Black women, who have higher baseline CVD risk, may derive greater absolute cardiovascular benefit from early MHT initiation, but no trial has been powered to test this hypothesis in a predominantly Black cohort.

Breast Cancer Risk by Race

The WHI estrogen-plus-progestin arm found a hazard ratio of 1.24 for invasive breast cancer. Black women have lower overall breast cancer incidence but higher rates of triple-negative subtypes, which are not estrogen-receptor-positive and thus may not be promoted by MHT. A 2020 analysis in Cancer Epidemiology found no significant MHT-associated breast cancer risk increase in Black women using estrogen-only therapy, a finding that should inform individualized counseling.

Progesterone Formulation Considerations

Micronized progesterone (Prometrium) carries a more favorable cardiovascular profile than synthetic progestins, per the E3N cohort study (N=80,377 French women). Given higher baseline CVD risk in Black and Hispanic women, clinicians prescribing combined MHT in these groups should default to micronized progesterone over medroxyprogesterone acetate where possible.

Visceral Adiposity Measurement: Why BMI Is Not Enough

Standard BMI cutoffs were derived from European populations and fail to capture metabolic risk equivalently across ethnicities. This is not a minor technical point. It directly affects who gets referred for pharmacotherapy and who gets told to "try diet and exercise."

DEXA and Waist Circumference as Better Proxies

The Endocrine Society's 2023 Obesity Guideline recommends waist circumference measurement alongside BMI, with sex-specific thresholds (≥88 cm in women) flagging abdominal obesity. For Asian women, an adjusted cutoff of ≥80 cm better identifies visceral risk, per IDF 2006 consensus criteria.

Cardiometabolic Risk Calculators

The pooled cohort equations used to estimate 10-year ASCVD risk include race as a coefficient, though a 2019 JAMA analysis found they overestimate risk in some racial groups and underestimate it in others. Clinicians should pair BMI and waist circumference with fasting insulin, HOMA-IR, triglyceride-to-HDL ratio, and HbA1c when assessing a perimenopausal woman of color.

Structural Determinants of Disparity

Individual biology explains only part of the racial gap in menopausal weight gain outcomes. Structural and social determinants account for a substantial proportion.

Neighborhood Food Environment

A 2021 American Journal of Preventive Medicine study found that Black and Hispanic women in low-food-access neighborhoods gained 1.4 kg more over a 5-year menopausal transition period than women in high-access areas, independent of income. Prescribing a Mediterranean diet without addressing food access is incomplete care.

Chronic Stress and Cortisol

Chronic race-based stress (weathering hypothesis) elevates cortisol chronically in Black women. Elevated cortisol promotes visceral adipogenesis and insulin resistance. A Psychoneuroendocrinology study documented higher salivary cortisol AUC in Black women reporting high perceived discrimination, with a direct association to waist circumference increase over 3 years.

Sleep Disruption

Black and Hispanic women report worse sleep quality during perimenopause than white women. SWAN sleep data show Black women had 2.1 times the odds of short sleep duration (<6 hours) compared to white women. Short sleep independently predicts weight gain via ghrelin upregulation and leptin suppression.

Clinical Decision Framework for Racially Equitable Menopause Weight Management

Applying one protocol to all perimenopausal patients will systematically under-treat high-risk groups. The following approach reflects current evidence and guideline recommendations.

Step 1: Adjust Risk Thresholds by Ancestry

Use BMI <23 as an "at-risk" flag for East and South Asian women. Apply waist circumference ≥80 cm (Asian) or ≥88 cm (other groups) as a trigger for metabolic workup. Order fasting lipids, HbA1c, and fasting insulin at perimenopause onset for Black, Hispanic, and AIAN women regardless of BMI.

Step 2: Offer Pharmacotherapy at Lower Thresholds for High-Risk Groups

AACE's 2016 Obesity Clinical Practice Guidelines support pharmacotherapy at BMI ≥27 with any comorbidity. Given visceral-fat underestimation by BMI in Asian and Hispanic women, initiating GLP-1 therapy at BMI ≥25 with documented metabolic syndrome is defensible in these groups pending race-stratified guideline updates.

Step 3: Address MHT Equity

Screen all perimenopausal women for MHT eligibility using the NAMS 2022 Position Statement criteria. Do not assume Black women are poor candidates based on misread WHI data. The WHI enrolled women at a mean age of 63, not the perimenopausal window where benefit-risk is most favorable.

Step 4: Integrate Social Determinants into the Plan

Document food security, neighborhood walkability, sleep quality, and occupational stress. Connect patients to community health workers and culturally concordant dietitians where available. These are not optional add-ons. A 2022 Annals of Internal Medicine review found that social-determinant interventions added to pharmacotherapy produced 2.3 kg greater weight loss at 12 months than pharmacotherapy alone in predominantly Black and Hispanic cohorts.